Jenburkt Pharmaceuticals Limited researches and develops, manufactures, and markets pharmaceutical and healthcare products in India. The company offers products in various therapeutic areas, such as pain management, analgesic and anti-pyretics, muscle relaxants, nutraceuticals, neuropathic pain, anti-arthritic, anti-infectives, antifungals, antiulcerants/antacids, aphrodisiacs, antimalarials, anthelmintics, cough and cold, and anti- diabetics, as well as consumer products. It offers its products under the Allerzine, CartiSafe Forte, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, Zydol Suspension, and Zixa brand names. It serves its products through stockists, doctors, pharmacies, chemists, large government, semi-government i
| Current Price | ₹1,141.55 |
|---|---|
| Market Cap | ₹504 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Non-Prescription Drugs |
| P/E Ratio | 14.5 |
| Return on Equity | 18.84% |
| 52-Week Range | ₹944.00 – ₹1,410.00 |
| Beta (1Y) | 0.37 |
| Dividend Yield | 1.81% |
1. Pharmaceutical Formulations-100%
Jenburkt Pharmaceuticals Ltd. is trading at ₹1,141.55, with a market capitalisation of ₹504 Cr.
Jenburkt Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Non-Prescription Drugs).
Jenburkt Pharmaceuticals Ltd. has a P/E of 14.5 and a return on equity of 18.84%.